| Sentinelle Medical | $85 Million | Exclusive Financial Advisor | Sale to Hologic | July 2010 |
| Mela Sciences | $17 Million | Joint Bookrunner | Follow-On Offering | June 2010 |
| Somanetics | $329 Million | Financial Advisor | Sale to Covidien | June 2010 |
| Pharmacyclics | $52 Million | Financial Advisor | Registered Direct Offering | June 2010 |
| Tengion | $30 Million | Joint Bookrunner | Initial Public Offering | April 2010 |
| Idenix Pharmaceuticals | $28 Million | Co-Manager | Registered Direct Offering | April 2010 |
| ExonHit Therapeutics | $32 Million | Financial Advisor | Acquisition of RedPath | April 2010 |
| Theravance | $99 Million | Joint Bookrunner | Follow-On Offering | March 2010 |
| Aveo Pharmaceuticals | $86 Million | Co-Lead Manager | Initial Public Offering | March 2010 |
| Amicus Therapeutics | $19 Million | Sole Placement Agent | Registered Direct Offering | February 2010 |
| Chelsea Therapeutics | $18 Million | Lead Placement Agent | Registered Direct Offering | February 2010 |
| AMAG | $174 Million | Co-Manager | Public Offering | January 2010 |
| InterMune | $114 Million | Co-Manager | Follow-On Offering | January 2010 |
| Quidel | $130 Million | Financial Advisor | Proposed Acquisition | January 2010 |
| ZymoGenetics | $97 Million | Sole Book-Running Manager | Underwritten Offering | January 2010 |
| Pharmasset | $34 Million | Sole Book-Running Manager | Underwritten Offering | January 2010 |
| Biogen Idec | $493 Million | Financial Advisor | Unsolicited Tender Offer for Facet Bioech | December 2009 |
| Dendreon | $427 Million | Co-Manager | Follow-On Offering | December 2009 |
| Addrenex Pharmaceuticals | $35 Million | Financial Advisor | Sale to Sciele Pharma, Inc. | November 2009 |
| AGA Medical | $199 Million | Active Book Running Manager | Initial Public Offering | October 2009 |
| Allos Therapeutics | $99 Million | Co-Lead Manager | Follow-On Offering | October 2009 |
| Prodesse | $85 Million | Financial Advisor | Sale to GEN-PROBE | October 2009 |
| Momenta | $50 Million | Sole Book-Running Manager | Follow-On Offering | September 2009 |
| Syneron | $68 Million | Sole Advisor | Merger with CANDELA | September 2009 |
| Peplin | $288 Million | Financial Advisor | Sale to LEO | September 2009 |
| Calypso Medical | $50 Million | Sole Agent | Private Placement | September 2009 |
| MAKO Surgical | $58 million | Co-Manager | Follow-on Offering | August 2009 |
| MAP Pharmaceuticals | $34 million | Co-Lead Manager | Follow-on Offering | August 2009 |
| Idenix Pharmaceuticals | $23 million | Sole Book-Running Manager | Registered Direct | August 2009 |
| Orexigen | $86 million | Sole Book-Running Manager | Follow-on Offering | July 2009 |
| Pharmasset | $45.5 million | Sole Placement Agent | Registered Direct | January 2009 |
| Sapphire Therapeutics | $130 Million | Exclusive Financial Advisor | Sale to Helsinn | January 2009 |
| Helicos BioSciences | $19 million | Sole Agent | PIPE | December 2008 |
| Momenta Pharmaceuticals | $25 million | Sole Placement Agent | Registered Direct | December 2008 |
| United Therapeutics | $150 million | Exclusive Financial Advisor | License Tadalafil from Lilly | December 2008 |
| VisiGen | $75 million | Exclusive Financial Advisor | Sale to Invitrogen Corp. | September 2008 |
| Cellzome | N/A | Exclusive Financial Advisor | License kinase technology to GlaxoSmithKline | September 2008 |
| Cardionet | $132 million | Co-Lead Manager | Follow-on Offering | July 2008 |
| Jazz Pharmaceuticals | $26 million | Co-Agent | Registered Direct | July 2008 |
| Pharmasset | $26 million | Co-Agent | Registered Direct | July 2008 |
| BG Medicine | $40 million | Sole Agent | Private Placement | July 2008 |
| Light Sciences Oncology | $40 million | Sole Agent | Private Placement | July 2008 |
| Sequenom | $98 million | Co-Manager | Follow-on Offering | June 2008 |
| Luminex | $80 million | Co-Manager | Follow-on Offering | June 2008 |
| Javelin | $28 million | Lead Agent | Registered Direct | May 2008 |
| Neurogen | $30 million | Co-Agent | Exchangeable Preferred Stock | April 2008 |
| Cardionet | $81 million | Co-Manager | IPO | March 2008 |
| superDimension | $22 million | Sole Agent | Private Placement | February 2008 |
| Biodel | $59 Million | Co-Manager | Follow-on Offering | February 2008 |
| Orexigen | $77 Million | Co-Lead Manager | Follow-on Offering | January 2008 |
| Cougar Biotechnology | $87 Million | Lead Agent | PIPE | December 2007 |
| Revance Therapeutics | $43 million | Sole Agent | Private Placement | December 2007 |
| Hologic | $1.7 billion | Co-Manager | Convertible Debt | December 2007 |
| Inverness Medical Innovations | $849 million | Co-Manager | Follow-on Offering | November 2007 |
| Enteromedics | $44 million | Co-Manager | IPO | November 2007 |
| Decision Biomarkers | Undisclosed | Sole Placement Agent | Private Placement | November 2007 |
| ARYx Therapeutics | $50 million | Co-Manager | IPO | November 2007 |
| Insulet | $131 million | Co-Manager | Follow-on Offering | November 2007 |
| Chelsea Therapeutics | $49 million | Lead Agent | Registered Direct | November 2007 |
| Nanosphere | $113 million | Co-Manager | IPO | October 2007 |
| Sequenom | $30 million | Co-Agent | PIPE | October 2007 |
| Targanta Therapeutics | $58 million | Co-Manager | IPO | October 2007 |
| Sucampo Pharmaceuticals | $43 million | Co-Manager | IPO | August 2007 |
| Hana Bioscienses | $50 million | Exclusive Financial Advisor | Licensing Agreement | August 2007 |
| Sangamo | $30 million | Co-Agent | Registered Direct | June 2007 |
| Transition Therapeutics | $24 million | Financial Advisors | PIPE | June 2007 |
| Light Scienses Oncology | $30 million | Placement Agent | Private Placement | June 2007 |
| Alsius | $85 million | Exclusive Financial Advisor | Sale to Ithaka Acquisition Corp. | June 2007 |
| ArQule | $54 million | Co-Manager | Follow-on Offering | June 2007 |
| Helicos | $49 million | Co-Manager | IPO | May 2007 |
| Insulet | $116 million | Co-Manager | IPO | May 2007 |
| Javelin | $43 million | Co-Manager | IPO | May 2007 |
| Biodel | $86 million | Co-Manager | IPO | May 2007 |
| Cougar Biotechnology | $50 million | Sole Agent | PIPE | May 2007 |
| Orexigen | $97 million | Co-Manager | IPO | April 2007 |
| Poniard | $75 million | Co-Manager | Follow-on Offering | April 2007 |
| Altus Pharmaceuticals | $96 million | Co-Manager | Follow-on Offering | April 2007 |
| Lightsciences | $15 million | Sole Placement Agency | Private Placement | March 2007 |
| TransMedics | $25 million | Sole Agent | Private Placement | March 2007 |
| Chelsea Therapeutics | $13 million | Sole Placement Agent | PIPE | March 2007 |
| TM Bioscience | $70 million | Exclusive Financial Advisor | Sale to Luminex | Febuary 2007 |
| Kosan | $46 million | Co-Agent | Registered Direct | Febuary 2007 |
| Ception | $63 million | Sole Placement Agent | Private Placement | January 2007 |
| Inverness Medical Innovations | $274 million | Co-Manager | Follow-on Offering | January 2007 |
| ISIS Pharmaceuticals | $125 million | Co-Agent | Convertible Debt | January 2007 |
| Cardiome Pharma | $97 million | Co-Manager | Follow-on Offering | January 2007 |
